Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Amy C. Burke"'
Autor:
Nadya M. Morrow, Amy C. Burke, Joshua P. Samsoondar, Kyle E. Seigel, Andrew Wang, Dawn E. Telford, Brian G. Sutherland, Conor O'Dwyer, Gregory R. Steinberg, Morgan D. Fullerton, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 387-402 (2020)
Obesity, dyslipidemia, and insulin resistance, the increasingly common metabolic syndrome, are risk factors for CVD and type 2 diabetes that warrant novel therapeutic interventions. The flavonoid nobiletin displays potent lipid-lowering and insulin-s
Externí odkaz:
https://doaj.org/article/4cda3eb4c2104e2fabdf5d55dfd633bf
Autor:
Amy C. Burke, Brian G. Sutherland, Dawn E. Telford, Marisa R. Morrow, Cynthia G. Sawyez, Jane Y. Edwards, Maria Drangova, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 9, Pp 1714-1728 (2018)
Obesity and its associated metabolic dysfunction and cardiovascular disease risk represent a leading cause of adult morbidity worldwide. Currently available pharmacological therapies for obesity have had limited success in reversing existing obesity
Externí odkaz:
https://doaj.org/article/761ce2d5872b400187ff5a277fcec253
Autor:
Murray W. Huff, Nadya M. Morrow, Conor O’Dwyer, Andrew Wang, Gregory R. Steinberg, Morgan D. Fullerton, Joshua P. Samsoondar, Kyle E. Seigel, Amy C. Burke, Dawn E. Telford, Brian G. Sutherland
Publikováno v:
Journal of Lipid Research, Vol 61, Iss 3, Pp 387-402 (2020)
J Lipid Res
J Lipid Res
Obesity, dyslipidemia, and insulin resistance, the increasingly common metabolic syndrome, are risk factors for CVD and type 2 diabetes that warrant novel therapeutic interventions. The flavonoid nobiletin displays potent lipid-lowering and insulin-s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca6500219509b0a717dcf54cb2ee8651
http://www.sciencedirect.com/science/article/pii/S0022227520435229
http://www.sciencedirect.com/science/article/pii/S0022227520435229
Publikováno v:
Current Opinion in Lipidology. 30:1-9
Bempedoic acid has emerged as a potent inhibitor of ATP-citrate lyase (ACLY), a target for the reduction of LDL cholesterol (LDL-C). We review the impact of bempedoic acid treatment on lipoprotein metabolism and atherosclerosis in preclinical models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b18e1c0b78ed249cf786a95a42387a1a
https://doi.org/10.1097/mol.0000000000000565
https://doi.org/10.1097/mol.0000000000000565
Publikováno v:
Sexualities. :136346072210881
In this article, the authors explore the place-based experiences of sex workers and how these experiences intersect with the juridical realm of sex work. The article begins with an overview of the model informing Canadian legislation, how these laws
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0afa6fe59f0c61332a5d93129341a9a
https://doi.org/10.1177/13634607221088150
https://doi.org/10.1177/13634607221088150
Autor:
Marisa R. Morrow, Brian G. Sutherland, Jane Y. Edwards, Dawn E. Telford, Amy C. Burke, Maria Drangova, Cynthia G. Sawyez, Murray W. Huff
Publikováno v:
Journal of Lipid Research, Vol 59, Iss 9, Pp 1714-1728 (2018)
Medical Biophysics Publications
Bone and Joint Institute
Medical Biophysics Publications
Bone and Joint Institute
Copyright © 2018 Burke et al. Obesity and its associated metabolic dysfunction and cardiovascular disease risk represent a leading cause of adult morbidity worldwide. Currently available pharmacological therapies for obesity have had limited success
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f221864abbec4ab66bd0eb13e40524dd
http://www.sciencedirect.com/science/article/pii/S0022227520335409
http://www.sciencedirect.com/science/article/pii/S0022227520335409
Autor:
Jane Y. Edwards, J. Geoffrey Pickering, Brian G. Sutherland, Cynthia G. Sawyez, Amy C. Burke, Murray W. Huff, Dawn E. Telford, P. Hugh R. Barrett, Roger S. Newton
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 38:1178-1190
Objective— Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d464461bfa4ff8f963650f27381fecd7
https://doi.org/10.1161/atvbaha.117.310676
https://doi.org/10.1161/atvbaha.117.310676
Autor:
Dawn E. Telford, Cynthia G. Sawyez, Roger S. Newton, Amy C. Burke, Murray W. Huff, Stephen L. Pinkosky, Jane Y. Edwards, Joshua P. Samsoondar, Brian G. Sutherland
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 37:647-656
Objective— Bempedoic acid (ETC-1002, 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid) is a novel low-density lipoprotein cholesterol–lowering compound. In animals, bempedoic acid targets the liver where it inhibits cholesterol and fatty acid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97e95f03c62b5a6eb562a5b8573ed22a
https://doi.org/10.1161/atvbaha.116.308963
https://doi.org/10.1161/atvbaha.116.308963
Autor:
Murray W. Huff, Amy C. Burke
Publikováno v:
Current opinion in lipidology. 29(2)
Regression, or reversal, of atherosclerosis has become an important clinical objective. The development of consistent models of murine atherosclerosis regression has accelerated this field of research. The purpose of this review is to highlight recen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed29749b5562c0b3de0f2c2e7bbdf2f5
https://pubmed.ncbi.nlm.nih.gov/29369832
https://pubmed.ncbi.nlm.nih.gov/29369832
Autor:
Amy C, Burke, Dawn E, Telford, Brian G, Sutherland, Jane Y, Edwards, Cynthia G, Sawyez, P Hugh R, Barrett, Roger S, Newton, J Geoffrey, Pickering, Murray W, Huff
Publikováno v:
Arteriosclerosis, thrombosis, and vascular biology. 38(5)
Bempedoic acid (BemA; ETC-1002) is a novel drug that targets hepatic ATP-citrate lyase to reduce cholesterol biosynthesis. In phase 2 studies, BemA lowers elevated low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic patients. In the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ace5120988ac6b5f7f89d8a9b9c580c1
https://pubmed.ncbi.nlm.nih.gov/29449335
https://pubmed.ncbi.nlm.nih.gov/29449335